{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 33,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a bar chart to show dose-dependent efficacy across three cognitive tests (HVLT, Symbol Coding, Category Fluency).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/9",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.62,
        "y": 0.38
      },
      "kind": "callout",
      "text": "Dose dependent, widespread qEEG changes observed across brain regions",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54f765bf-6bb3-43ca-b573-2f3b5d25213c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.37,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Phase 2 PoM Trial Efficacy Data showing T-Scores for HVLT, Symbol Coding, and Category Fluency across 10mg, 20mg, 40mg, and 80mg doses.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "026479dc-d508-4edb-b24a-23d5fa2b280b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; HVLT = Hopkins Verbal Learning Test; TID = 3x/day dosing; PoC = Proof of Concept, PoM = Proof of Mechanism. Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of September 30th, 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fd3e7ca-b652-4f3a-ab0d-d0679214ad4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.37,
        "y": 0.18
      },
      "kind": "quote",
      "text": "Symbol coding response is at a level that would correlate with better work/school performance",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b34d6902-c4c6-4bd8-8deb-914c3213cbdd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.87,
        "y": 0.57
      },
      "kind": "source-note",
      "text": "Cohen's d* (Symbol Coding): 20 mg: 0.79, 40 mg: 0.56, 80 mg: 0.38",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5b3fb34-f61c-4bf9-aa2b-107577630cd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.32,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "table",
      "text": "Ownership: 51.9% | Product: RL-007 | Pharmacology: GABA/nicotinic modulator | Features: Pro-cognitive effects | Indications: CIAS | Status: Phase 2a/2b | IP: Patents | Highlight: Phase 2 results",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffd9520d-a134-4f39-a03b-e0abcbc1edc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.37,
        "y": 0.07
      },
      "kind": "title",
      "text": "RL-007 has previously shown pro-cognitive effects in human clinical studies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c7f46f6-72d7-4d92-b52d-fe8e3793fd74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98c26bf0-90f3-46bb-b0fb-81a70cb6d49b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "02334c08-2546-46ea-a541-f46be248cf06",
      "evidence": "This slide presents a concise summary of RL-007's pro-cognitive effects in human clinical studies.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "1c2bcbb0-1a5b-42d4-b120-9d2db911b3fd",
      "evidence": "Structured summary of product, status, and data",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "707b84bb-d006-4ebc-b566-ffd6845e4351",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The presentation identifies a huge need for development in CIAS and Schizophrenia treatment (p8) and an urgent need for innovation in depression treatment (p15).",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7aa520a4-e861-4ddd-adb0-33d2e2059fa2",
      "evidence": "The presentation highlights the huge need for development in CIAS and Schizophrenia treatment (p8) and the urgent need for innovation in depression treatment (p15).",
      "position": 0,
      "objective": "What are the consequences of not addressing mental health disorders?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}